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Abstract 
Synthetic sick or synthetic lethal (SS/L) screens are a powerful way to identify 
candidate drug targets to specifically kill tumor cells but this approach generally 
suffers from low consistency between screens. We found that many SS/L 
interactions involve essential genes and are therefore detectable within a limited 
range of knockdown efficiency. Such interactions are often missed by overly efficient 
RNAi reagents. We therefore developed an assay that measures viability over a 
range of knockdown efficiency within a cell population. This method, called variable 
dose analysis (VDA), is highly sensitive to viability phenotypes and reproducibly 
detects SS/L interactions. We applied the VDA method to search for SS/L 
interactions with TSC1 and TSC2, the two tumor suppressors underlying tuberous 
sclerosis complex (TSC) and generated a SS/L network for TSC. Using this network, 
we identified four FDA-approved drugs that selectively affect viability of TSC deficient 
cells, representing promising candidates for repurposing to treat TSC-related tumors. 
 
Significance statement 
Synthetic sick or lethal (SS/L) interactions occur when disruption of two genes 
reduces cell viability to a greater extent than expected based on the individual gene 
disruptions. SS/L interactions involving tumor suppressors represent candidate drug 
targets for cancers because treatment is expected to kill tumor cells carrying the 
tumor suppressor mutation but leave healthy cells unaffected. Identification of SS/L 
interactions is of vital importance to develop new therapies for tumorigenic disease. 
We have developed an RNAi-based approach called variable dose analysis (VDA), 
which improves both sensitivity and robustness to noise compared to dsRNA-based 
methods for screening in Drosophila. Using this method, we identified four FDA-
approved drugs with specific effects on cells deficient for the TSC1 and TSC2 tumor 
suppressor genes.  
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Introduction 
A genetic interaction occurs when the combined disruption of two genes produces a 
phenotype that differs from that expected based on the effects of each individual 
gene disruption. One type of genetic interaction in which cell viability is reduced only 
following combined disruption of two genes but not following disruption of either gene 
alone is called a synthetic sick or synthetic lethal (SS/L) interaction depending on the 
severity of the viability effect. SS/L interactions have received considerable interest 
for the development of drug targets for cancers because targeting of a gene that has 
a SS/L interaction with a tumor suppressor is expected to specifically reduce viability 
of tumor cells but leave wild-type cells unaffected (1–3). In addition, large-scale 
knowledge of SS/L interactions can be used to gain functional insight into individual 
genes and network structures (4–6). 
 
SS/L screens have been performed covering most of the possible pairwise gene 
combinations in the yeast Saccharomyces cerevisiae, leading to insight into the 
global molecular wiring of a cell (6). Furthermore, SS/L screens have been 
performed with the aim of identifying drug targets in cultured mammalian cells, 
including tumor-derived lines (e.g. Luo et al. 2009; Cowley et al. 2014; Hart et al. 
2015; Wang et al. 2017). However, SS/L screens in general have suffered from 
limited consistency between screens and have resulted in the identification of 
relatively few effective drug targets (2, 11–13).  This may in part be due to the noisy 
nature of high-throughput screens.  However, a major contributor to this lack of 
concordance between studies is likely to be context dependence of cancer cell line 
dependencies, as illustrated by widely varying responses to existing therapeutic 
agents (14, 15). Thus SS/L interactions can be classified either as ‘hard’ interactions, 
which function independent of genetic or cellular context or ‘soft’ interactions which 
may reflect cell context (i.e., the genes expressed in one cell line versus others or 
growth conditions) (10, 16). Consistent with this, a recent study in which SS/L 
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interaction screens were performed in multiple Ras-dependent and Ras-independent 
acute myeloid leukemia (AML) cell lines found relatively few dependencies common 
specifically to Ras-dependent lines, suggesting that the majority of Ras-induced 
dependencies are specific to an individual context (10). These issues highlight the 
need to develop robust SS/L screening methods and assess SS/L interactions 
across diverse genetic backgrounds in order to find effective drug targets that will 
function in many contexts. 
 
Towards this goal, we reported previously the use of a cross-species screening 
approach to identify SS/L interactions with TSC1 and TSC2, the two tumor 
suppressor genes underlying tuberous sclerosis complex (TSC) (17, 18). We 
performed focused dsRNA screens targeting all kinases and phosphatases in wild-
type, TSC1 and TSC2 mutant Drosophila cells. By comparing screens, we identified 
three genes that specifically reduce viability of TSC1 and TSC2 mutant cells when 
knocked down. All three had conserved SS/L interactions with TSC2 in mouse and 
human cell lines, illustrating the potential of this approach to identify candidate drug 
targets relevant to humans. By performing these screens in Drosophila and then 
validating hits in diverse mammalian systems, we hoped to identify core SS/L 
interactions that were not specific to a single human cell type. 
 
Here, we report an additional advance towards improved SS/L screening methods. 
Using a similar cross-species screening approach, we performed genome-wide 
screens to identify SS/L interactions with the TSC1 and TSC2 genes. Analysis of 
screen results and comparison between screens revealed that many SS/L 
interactions were missed in each screen, consistent with the low rate of consistency 
between previous screens. Further investigation revealed that many SS/L 
interactions involve essential genes that were likely missed due to overly efficient 
knockdown, which reduced the viability of both wild-type and TSC1/2 mutant cells. 
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We therefore developed a new RNAi-based screening assay that measures 
phenotypes over a range of knockdown efficiencies in a single sample. This method 
improved signal to noise ratio in viability assays by approximately 2.5-fold compared 
to dsRNA assays and detected 86% of positive control SS/L interactions. Using this 
method in combination with our previous screen results and other pre-existing 
datasets, we generated a high-confidence SS/L interaction network surrounding the 
TSC complex. Finally, using this network we identified four FDA-approved drugs 
showing selective effects on the viability of TSC deficient cells that may represent 
promising candidates for drug repurposing to treat TSC tumors. Importantly, all four 
of these drugs showed conserved effects in three mammalian cell culture models of 
TSC, including two diverse tumor-derived cell lines, illustrating that this screening 
approach improves the identification of context-independent candidate therapeutic 
drugs.  
 
Results 
SS/L interactions are enriched for essential genes 
To identify SS/L interactions with the TSC complex, we performed SS/L interaction 
screens using two dsRNA libraries. The first targeted 13,099 genes, representing the 
majority of the Drosophila genome. The second library targeted 466 Drosophila 
orthologs of putative targets of FDA-approved drugs. By screening this group of 
genes with high coverage, we improved the chances of identifying SS/L interactions 
with genes for which clinically-approved drugs already exist, which therefore may be 
rapidly repurposed for clinical use to treat TSC tumors. From these two screens, 288 
genes were identified that had SS/L interactions with TSC1 and/or TSC2 (Tables S1 
and S2). Replicate screens showed good correlation in general, indicating that the 
results are sound (Figure 1A). We note that the genome-wide screen results had 
lower correlation coefficients than the FDA screens. This is likely due to edge effects, 
which are avoided in the FDA library by leaving edge wells empty. To confirm the 
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validity of these hits, we selected five genes from the genome-wide screen with 
varying confidence levels and tested whether their human orthologs also showed 
SS/L interactions with TSC2 in a tumor-derived human cell line. Similar to the high 
validation rate in mammalian systems observed in our previous studies (18), all five 
SS/L interactions were validated in this system (Figure 1B). Furthermore, two 
additional genes not expected to show SS/L interactions with TSC1 or TSC2 showed 
no selective viability effect in similar assays performed previously (18), indicating that 
the TSC2 addback cells are not simply less sensitive to viability changes. 
 
Despite the apparent high quality of the SS/L interactions identified, relatively little 
overlap was observed between the independent libraries screened. For example, a 
total of 50 SS/L genes were screened in the combined KP/FDA libraries and the 
genome-wide screen, yet only 2 were identified as SS/L in both datasets. In addition, 
only 4.6% of the identified SS/L interactions in these screens were observed with 
multiple independent dsRNA reagents despite the fact that 67% of SS/L genes were 
represented by more than one dsRNA in the screens. This observation is consistent 
with the limited consistency between SS/L screens previously performed in 
mammalian systems likely being due to the use of different RNAi reagents. To 
investigate the reasons underlying the inconsistency between dsRNA reagents and 
screens, we assessed the effects of dsRNA reagents that did not identify SS/L 
interactions despite targeting genes that were identified as SS/L using independent 
dsRNA reagents. We found that approximately 72.5% of reagents had no detectable 
effect on viability in either wild-type, TSC1 or TSC2 mutant cells and likely represent 
ineffective reagents. By contrast, 27.5% of reagents failed to identify SS/L 
interactions because they reduced viability of all cell types, suggesting that their 
targets are essential genes or that the viability effects are due to disruption of off-
target genes (Table S3). In addition, the 288 SS/L genes identified from the screens 
were highly enriched for known essential genes identified in multiple previous studies 
	 7	
(Figure 1C). These results indicate that genes with SS/L interactions are enriched for 
essential genes, consistent with previous observations in yeast (6). Furthermore, we 
found that genes identified from SS/L screens in mammalian systems with activated 
Ras or Myc, also showed enrichment of essential genes (Figure 1D), suggesting that 
this is a general property of SS/L interactions. 
 
Variable Dose Analysis (VDA) allows sensitive detection of viability phenotypes 
SS/L interactions involving essential genes are detectable within a limited range of 
target gene knockdown efficiency because weak knockdown is ineffective and strong 
knockdown is lethal to both wild-type and mutant cells. Therefore, to improve 
detection of this type of SS/L interaction, an assay is required that allows 
assessment of viability effects over a range of target gene knockdown efficiencies. 
To achieve this, we took advantage of the variable efficiency of plasmid transfections 
between individual cells in a population, resulting in variable plasmid copy number in 
each cell. By co-transfecting a GFP expressing plasmid and a shRNA expressing 
plasmid, the GFP intensity can be used as an indirect readout of shRNA expression 
and therefore target gene knockdown efficiency (Figure 2A). We named this method 
variable dose analysis (VDA). To test the correlation between GFP expression and 
knockdown efficiency using this approach, we used S2 cells that express mCherry 
from a genomic transgene insertion into the CLIC locus (19). VDA assays were 
performed in this cell line targeting either a control gene (white) or the mCherry 
transgene. mCherry fluorescence was then compared to GFP fluorescence and 
mCherry fluorescence was found to decrease as GFP intensity increased with a non-
linear relationship (Figure 2B). Therefore, GFP fluorescence can be used as a 
measure of relative target gene knockdown efficiency. 
 
Next, we performed experiments to assess the sensitivity of this method relative to 
an established viability assay. We co-transfected the GFP reporter plasmid with 
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shRNA plasmids targeting thread, an apoptosis inhibitor that robustly induces cell 
death when inhibited, or a control gene, white. Signal strength was varied by serially 
diluting the thread shRNA plasmid with white shRNA plasmid. In addition, the same 
samples were analysed using CellTiter-glo (CTG) assays, a standard readout that 
has been widely used in high-throughput viability screens. We found that VDA 
outperformed CTG assays for detection of weak phenotypes and p-values remained 
highly significant even when the thread shRNA was diluted 256-fold compared to the 
standard dose (Figure 2C-E). 
 
Finally, in order to directly compare VDA with established dsRNA-based methods, 
we generated three pairs of positive and negative control shRNAs for cell viability 
targeting thread and white respectively. We then performed VDA assays in S2R+ 
cells and calculated Z’ scores for each pair of reagents. In addition, we used three 
pairs of positive and negative control reagents from the DRSC dsRNA collection (20, 
21) and performed similar assays using a CTG readout. Comparison between these 
results showed that the Z’ scores for VDA assays were consistently higher than for 
dsRNA assays, corresponding to an increase in signal-to-noise ratio of approximately 
2.5-fold (Figure 2F). In addition, VDA assays had reduced variation between control 
reagent pairs, indicating that these assays may be more robust to differences in 
reagent efficiency.  
 
Overall, these experiments demonstrate that VDA is a highly sensitive and robust 
method for the detection of viability phenotypes. 
 
VDA assays efficiently identify SS/L interactions with essential and non-essential 
genes 
In order to test whether VDA assays are able to robustly identify known SS/L 
interactions with both essential and non-essential genes, we generated three shRNA 
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reagents per gene targeting 27 genes identified as SS/L in the dsRNA screens. In 
addition, to assess the ability of VDA assays to identify SS/L interactions with 
essential genes, we included 3 genes that were identified as essential (lethal to all 
cell types) but that had Z-scores at least 1.5-fold lower in both TSC1 and TSC2 
mutant cells compared to wild-type. Of these 30 genes, 18 were identified as 
essential genes in previous screens (20, 22, 23). 
 
SS/L interactions were identified as shRNA reagents that cause a significantly 
greater viability reduction in TSC1 cells compared to wild-type. 70.4% (19/27) of 
positive control genes were identified as having significant SS/L interactions with 
TSC1, illustrating the high sensitivity of this assay (Figure 2G, Table S4). In addition, 
the three genes that failed to score as SS/L in dsRNA assays due to viability effects 
in wild-type cells were all identified as SS/L using this assay. Finally, 33% of the 
genes assessed were identified as SS/L with multiple shRNA reagents (Figure 2G, 
Table S4), indicating a higher rate of consistency between reagents compared to 
dsRNA assays. 
 
Notably, SS/L interactions were not identified for 8 positive control genes. Viability 
phenotypes were detected for all but one of these genes, indicating that the failure of 
validation was not due to ineffective reagents. Another possible explanation is that, in 
addition to affecting cell viability, these genes alter cell size specifically in TSC1/2 
deficient cells and are therefore detected as SS/L in the ATP-based assays used in 
the dsRNA screens but not in cell count-based VDA assays. To assess this 
possibility, VDA data were re-analyzed as before but GFP measurements were 
normalized to cell sizes based on forward-scatter (FSC) readings collected in parallel 
with GFP fluorescence data. This allows detection of cell size phenotypes as well as 
viability effects. Using this analysis approach, 28/30 genes tested were identified as 
SS/L and 19 were identified with multiple reagents (Figure 2H, Table S4). This 
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demonstrates the ability of VDA assays to detect multiple different phenotypes in a 
single assay and to characterize hits in more detail than simple ATP-based assays. 
 
Given the improved ability of VDA assays to identify known SS/L interactions 
compared to the dsRNA/CellTiter-glo assays used in our previous screens, we used 
this method to screen 154 genes that can be targeted with well-characterized FDA-
approved drugs in wild-type, TSC1 and TSC2 cells. 44 genes were identified as 
having SS/L relationships with TSC1 and/or TSC2 (Table S5). Surprisingly, only 1 
gene (porin) was identified by both VDA and dsRNA assays. TSC1 and TSC2 act 
together in a protein complex and are thought to share the majority of their functions. 
Therefore, as SS/L interactions are related to gene function, these genes are 
expected to have similar SS/L interaction profiles. To assess the relative quality of 
dsRNA and VDA screens, we therefore compared SS/L interactions identified with 
TSC1 or TSC2 for each method. We selected the top 20 genes from dsRNA and 
VDA screens in TSC1 and TSC2 cells based on either VDA-scores or differences in 
z-score compared to wildtype cells. For dsRNA assays, 11% (4/36) of top ranked 
SS/L genes were identified with both TSC1 and TSC2. By contrast, for VDA assays, 
33% (10/30) top ranked SS/L genes were shared, suggesting that VDA is a much 
more robust method for identification of SS/L interactions (Figure 3A). 
 
Integrated analysis of SS/L screen data results in a high-quality SS/L network that is 
predictive of selective drug effects 
Previous studies have shown that genes that physically interact and have related 
functions share SS/L interaction partners (5, 6). Therefore, in order to identify the 
most robust hits from the screens and remove false positives, the hits from the 
dsRNA and VDA screens were pooled (331 genes) and mapped onto high-
confidence (score >0.9) protein-protein interaction (PPI) network using the STRING 
database (24) and clustered the genes based on their PPIs to identify those most 
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likely to have related functions. Due to the relatively low coverage of PPI data, we 
also manually assigned genes to clusters in cases where gene functions were known 
to be similar based on literature annotation (Figure 3B, Table S6). Using this 
approach, we defined 18 biological processes, each of which were identified as SS/L 
with the TSC complex by multiple genes. 14 of these processes were supported by 
both dsRNA and VDA screen results. Furthermore, three of the processes have been 
identified previously as dependencies of TSC deficient cells (e.g. ROS (oxidative 
stress), proteasome (protein catabolism) and lipid metabolism (25–31)) indicating 
that the network is a robust representation of the functional interactions of the TSC 
complex. Finally, 86.4% (38/44) of the genes identified using VDA assays were 
assigned to clusters, compared to 68.4% (197/288) of genes identified using 
dsRNAs, suggesting that VDA is a more reliable approach for detection of genuine 
SS/L interactions. 
 
Genes within the SS/L interaction network represent candidate drug targets to 
specifically reduce viability of TSC deficient tumor cells. We therefore selected nine 
FDA-approved drugs that target high-scoring components of the SS/L network and 
tested for specific viability effects on TSC2-deficient Drosophila cells. Of these, four 
had a greater effect on the viability of TSC2 cells compared to wild-type (Figure 4A). 
In addition, all four of these drugs had conserved effects on TSC2-deficient MEFs, 
TSC2-deficient renal angiomyolipoma (RA) derived human cells and TSC1-deficient 
bladder cancer derived human cells (32) (Figure 4B-D), although the quantitative 
difference in viability effect varied between cell types. Thus, the combined use of 
improved screening methods with a network-based analysis approach is a powerful 
method to identify drugs with reproducible viability effects specific to a given genetic 
background. 
 
Discussion 
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SS/L interaction screens have long been considered as a powerful approach for drug 
target discovery, yet have resulted in the identification of relatively few effective 
drugs. This appears to be due at least in part to a lack of consistency between 
screens despite apparently robust results within studies (13). Two technical factors 
likely contribute to this lack of consistency. First, high-throughput screens are 
inherently noisy, resulting in both false-positive and false-negative results. Second, 
as we and others have shown (6), SS/L interactions are enriched for essential genes, 
which are often missed due to overly efficient gene disruption, resulting in general 
toxicity to all cell types. In particular, this is likely to be an issue for CRISPR screens, 
which often result in null mutations of the target genes. 
 
In this study, we have addressed both of these issues. First, we developed a novel 
assay for synthetic lethality called VDA. This approach enables differences in viability 
between genetic backgrounds to be measured over a range of knockdown 
efficiencies and can therefore detect SS/L interactions with essential genes at sub-
lethal efficiency. In addition, the VDA method is more sensitive and robust to noise 
than other well-established methods to measure cell viability in Drosophila high-
throughput screens. Finally, by combining results from two independent screening 
technologies using a network-based analysis method we have generated a high-
confidence SS/L interaction network for the TSC complex. The quality of this network 
is illustrated by the identification of four effective FDA-approved drugs that represent 
promising candidates for new therapeutic strategies to treat TSC tumors.  
 
Of the four drugs identified, all have previously shown promise as therapeutic targets 
for cancers. For example, vorinostat and regorafenib are FDA-approved for the 
treatment of a number of different cancers and are under investigation for multiple 
others. In addition, lithium has shown anti-proliferative, apoptotic or anti-metastatic 
effects in multiple cancer models (33–36) and orlistat has been shown to inhibit 
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breast cancer cell proliferation (37). Orlistat likely functions in this context by 
reducing the availability of lipids, upon which TSC-deficient cells are known to be 
dependent (29). The mechanism by which lithium functions in this context is less 
obvious. Lithium has been used for over five decades for the treatment of bipolar 
disorder and is efficacious in this role (38, 39). However, despite the long history of 
clinical use, the mechanism of lithium’s action remains poorly understood (40). 
Multiple proteins have been identified as direct targets of lithium (e.g. IMPA1, IMPA2, 
GSK3 and GRIA3; https://www.drugbank.ca) but the effect of this drug in treating 
bipolar disorder has not been robustly linked with any of these proteins. In addition, 
lithium can disrupt protein function by displacing magnesium ions (41). Given that 
many hundreds of proteins rely on magnesium ions as a cofactor for their function 
(including all enzymes that utilise ATP), the mechanism of lithium’s action may 
involve complex effects on many different proteins, thus explaining the difficulties 
encountered in determining a single therapeutic target. Thus, while this may 
represent a promising candidate for the treatment of TSC, determining the 
mechanism by which the selective effect is achieved may be challenging. 
 
In addition to the technical issues associated with SS/L screens, context dependence 
of SS/L interactions is also likely to reduce consistency between screens in different 
experimental systems. A common approach to limit this effect is to perform screens 
in systems that are as closely related to the target tumors as possible, often using 
tumor-derived cells. More recently, efforts to identify SS/L interactions in panels of 
divergent cell lines sharing a common tumorigenic driver mutation have been used to 
identify shared dependencies (9, 10, 42). However, this approach requires extensive 
screening and is limited by high costs and available well-characterized cell lines. 
Instead, we chose an experimental paradigm in which screens are performed in 
Drosophila cells, which represent a genetic background highly divergent from the 
target human tumors. Given that many SS/L interactions are highly conserved (43), 
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our expectation was that SS/L interactions identified in Drosophila cells that could be 
validated in mouse or human cell lines would represent fundamental context-
independent interactions (‘hard’ interactions), which may therefore have a higher 
success rate when transferred to mammalian systems and to clinical use. Strikingly, 
we found that of eight SS/L interactions identified in our Drosophila screens, all could 
be validated in divergent mammalian cell lines (Figure 1B and (18)). One possible 
explanation of this is that the increased complexity of mammalian genomes 
compared to Drosophila results in greater network plasticity and therefore more ‘soft’ 
interactions. In this case, SS/L interactions identified in Drosophila have a greater 
chance of being context independent and therefore more likely to be conserved 
between divergent systems. This possibility is supported by the similar effects 
observed for the four identified drugs in diverse backgrounds including mouse and 
human tumor-derived cell lines. In particular similar effects were observed in bladder 
cancer-derived cells, which have one of the highest mutation rates of any cancer 
type (44), likely resulting in a highly divergent genetic background compared to the 
mouse and RA-derived cells. 
 
Previous screening approaches have generally focused on developing the most 
efficient RNAi reagents possible to maximize resulting phenotypes (45–47). More 
recently, CRISPR has emerged as a powerful screening technology to generate 
primarily null mutations in target genes and therefore further increases phenotype 
strength (48, 49). However, these screening paradigms, based on maximizing target 
gene disruption efficiency, may often be less representative of effects that can be 
achieved with small molecule inhibitors, which generally incompletely inhibit their 
targets (47). It is therefore possible that approaches that are optimized for efficient 
gene disruption may result in a lower rate of consistency with pharmacological 
assays. In this case, genes identified using VDA may be expected to have more 
consistent effects using pharmacological assays because phenotypes can be 
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detected at a relatively low gene disruption efficiency. Consistent with this, three of 
the four drugs identified in this study were detected only using VDA assays and only 
one (vorinostat) was identified by both VDA and dsRNA assays. However, neither 
approach was able to quantitatively predict specific drug effects with no correlation 
detected between screen score and pharmacological selectivity (Figure S1), likely 
due to differences in the mechanism of disruption between RNAi and small molecule 
inhibitors (47). Thus, identification of the most promising targets for pharmacological 
targeting remains a complex and unresolved issue. 
 
Despite the clear advantages of VDA over the previous dsRNA-based methods 
available for screening in Drosophila cells, there are some limitations, which must be 
overcome to enable the use of VDA in other systems and for other applications. In 
particular, VDA requires the use of transfection, which may limit its use in 
mammalian cell lines to those that are readily transfected without the use of viruses. 
In addition, the use of GFP as a reporter of transfection efficiency may result in non-
specific toxicity when expressed at high levels in some cell lines. Furthermore, VDA 
requires higher cell numbers per sample compared to viability assays performed 
using a CellTiter-glo readout. Therefore, screens must be performed in 96-well 
format, reducing the throughput. In addition, the cytometry readout requires 
approximately 25 minutes to analyse each 96-well plate compared to 1-2 minutes per 
384-well plate in CellTiter-glo assays. Finally, while we have delivered shRNA 
plasmids and the GFP reporter as separate plasmids, it is likely that combining these 
elements onto a single construct will improve results of future VDA applications 
especially in systems where plasmids are not necessarily delivered with constant 
ratio. Thus, further methodological developments will be needed in order to allow 
VDA screens to be fully exploited for a wide range of screening applications. 
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Materials and Methods 
Construction of the FDA RNAi libraries 
We retrieved the FDA drug list from DrugBank (Version 4.0, www.drugbank.ca) and 
extracted drug gene targets using the DrugBank.xml file. Human drug target genes 
were mapped to Drosophila genes using DIOPT vs4.0 (50) and only the high-
confident orthologous relationships supported by at least 7 different algorithms were 
selected for Drosophila FDA target libraries.  The final FDA library contains 458 
Drosophila genes. 2 quality amplicons were selected to make the dsRNA library (21) 
while 3 different shRNAs were designed based on DSIR tool (51) and were cloned 
into Valium20 vector (52) to make the shRNA library for VDA assays. 
 
dsRNA screens 
dsRNA screens were performed using the genome-wide and FDA libraries available 
from the Drosophila RNAi Screening Center (http://fgr.hms.harvard.edu), following 
the bathing protocol (http://fgr.hms.harvard.edu/fly-cell-rnai-384-well-format). Hits 
from each replicate screen were defined using a Z-score cutoff of -1.5. SS/L hits from 
the genome-wide screen were identified as dsRNA reagents that did not score in 
either replicate screen in S2R+ cells but scored in both replicate screens in TSC1 
cells and both replicates in TSC2 cells (high confidence), both replicates of either the 
TSC1 or TCS2 screen (medium confidence) or one replicate from each of the TSC1 
and TSC2 screens (low confidence). 
 
VDA assays 
VDA assays were performed by first transfecting a mixture of 10ng actin-GFP, 45ng 
actin-Gal4 and 45ng shRNA plasmids into wild-type, TSC1 or TSC2 cells seeded into 
96-well plates with 30,000 cells per well, following the standard Effectene 
transfection reagent protocol (Qiagen – 301427). Following 5 days of culture at 25°C, 
culture plates were analyzed using a BD LSR II flow cytometer. 20,000 events were 
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measured per sample and GFP intensities and FSC measurements were exported 
for all GFP expressing cells as .csv files for further analysis. 
 
Cytometry data were analyzed using custom Matlab scripts by first normalizing all 
GFP intensities to cell size measurements (FSC). Next, events were divided into 500 
bins based on GFP fluorescence and GFP distributions normalized between all 
samples. Finally, area under cumulative GFP distribution plots were calculated and 
compared to negative and positive control samples to calculate viability scores. 
 
Viability scores were calculated as the area between cumulative distribution plots for 
each sample and median negative control cumulative distribution plot for each plate 
(based on 5 negative controls targeting the white gene per plate) divided by the area 
between the sample curve and the median positive control curve (based on 5 
positive controls targeting the thread gene per plate). VDA scores were calculated as 
viability score in TSC1 or TSC2 cells minus viability score in wild-type cells. 
 
The VDA-score cutoff of 0.1 used to identify SS/L interactions was determined by 
performing 12 replicate VDA assays on each of 6 shRNA reagents determined 
previously to have no selective effect on TSC deficient cells (18). We then 
determined the VDA-score corresponding to a Z-score of 1.5 based on the 
distribution of VDA-scores from this negative control dataset. 
 
Hits were selected as genes that scored with a VDA score ≥ 0.1 in at least two 
replicates of the relevant screen and scored either with multiple shRNA reagents or a 
single reagent in both TSC1 and TSC2 screens. 
 
shRNA assays in human RA tumor-derived cells 
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Renal angiomyolipoma (RA) cells with stable vector (621-102) or TSC2 (621-103) 
addback (53) were cultured in DMEM (VWR #45000-312) +10% heat inactivated 
Fetal Bovine Serum (ThermoFisher Scientific #10437-028) +1X 
penicillin/streptomycin, (CellGRO 30-002-CI). Cells were transfected with shRNA 
targeting ARCN1, CRNKL1, SNW1, CTNS, or MFN1 (3 non-overlapping shRNAs per 
target) in pLKO.1 vector using Lipofectamine 3000 transfection reagent 
(ThermoFisher Scientific #L3000015) according to manufacturer’s instructions. A 
scrambled shRNA in pLKO.1 vector was transfected as a control. 6hrs after 
transfection, cells were washed with 1X PBS and fresh growth media was added. 
Cell viability was measured 48hr later using the Cell Titer Glo Luminescent Cell 
Viability Assay (Promega #G7573) according to manufacturer’s instructions. The 
following shRNA constructs were purchased from the Dana Farber/Harvard Cancer 
Center Plasmid Information Database (PlasmID): HsSH00157011, HsSH00157016, 
HsSH00157036, HsSH00167269, HsSH00167262, HsSH00167285, 
HsSH00152131, HsSH00152139, HsSH00152225, HsSH00116873, 
HsSH00116854, HsSH00116860, HsSH00157364, HsSH00157314, 
HsSH00157319. 
 
Network analysis 
SS/L genes identified from dsRNA and VDA screens were pooled and the online 
STRING database tool (24) used to identify high confidence (score ≥ 0.9) protein-
protein interactions (PPIs) and cluster the genes. In addition, gene functions were 
annotated manually based on Drosophila or human data in cases where clear 
orthologs could be identified. Additional SS/L genes were added to network clusters 
and new clusters created in cases where several genes shared similar functions. The 
network map was generated using Cytoscape (54). 
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Figure Legends 
Figure 1: SS/L interactions are enriched with essential genes. A) Bar graph 
illustrating the correlation coefficients between pairs of replicates from the genome-
wide (GW) or FDA screens as indicated. For the FDA screens, the numbers in 
brackets indicate which replicates are compared in each case. B) Bar graphs 
showing relative viability of TSC2-deficient renal angiomyolipoma (RA)-derived cells 
with either TSC2 cDNA (blue bars) or empty vector (red bars) addback transfected 
with the indicated shRNA constructs relative to control shRNA transfection, 
measured using CellTiter-glo assays. Bars represent average values from nine 
replicates in each case and error bars indicate standard error of the mean. Asterisks 
indicate cases where viability of empty vector addback samples is significantly lower 
than TSC2 cDNA addback samples (p<0.05) as determined using t-tests. The 
confidence class with which each gene was identified in the genome-wide screen is 
indicated below the gene names (Hi – High confidence and Med – Medium 
confidence). C) Bar graph showing fold enrichment of essential genes amongst SS/L 
genes identified from the genome wide screen. Three independent datasets were 
used to define essential (Hart (22), Boutros (20) and Wang (23)) or non-essential 
genes (Hart-NE (22)). Asterisks indicate statistically significant enrichment (p<0.05) 
based on z-tests to compare with 1000 permutations of randomly selected genes. D) 
Bar graph illustrating the % of genes identified as SS/L with Ras or Myc 
overexpression or activation in previous studies. “Genome” indicates the % essential 
genes in the whole genome assessed using the same datasets as in panel C 
combined to define essential genes (20, 22, 23). 
 
Figure 2: Variable Dose Analysis (VDA) is an effective method to measure 
viability phenotypes and detect SS/L interactions. A) Schematic illustrating the 
experimental setup of VDA assays. B) Graph illustrating the relationship between 
GFP fluorescence and target gene knockdown efficiency. mCherry fluorescence was 
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used as a measure of knockdown efficiency and is displayed as a fold change to 
cells with no detectable GFP expression. Each line represents the average of three 
biological replicate experiments using an independent shRNA reagent targeting 
mCherry (dashed lines) or white (solid lines). Error bars indicate standard error of the 
mean. C-D) Graphs showing cell viability measured using either VDA (C) or CellTiter-
glo (CTG) (D) assays over a range of thread RNAi dilutions. Measurements are 
normalised to both positive (thread RNAi) and negative (white RNAi) controls to allow 
simple comparison between the two methods. Lines show average readings from six 
replicates in each case. Multiple groups of replicates are shown to better illustrate 
consistency between experiments. Error bars indicate standard error of the mean. E) 
Graph illustrating the improved ability of VDA assays (blue line) to detect viability 
phenotypes compared to CellTiter-glo assays (red line) performed on the same 
populations of cells. Dashes represent –log10 p-values calculated from three 
independent groups of six replicate experiments. The lines represent the median 
value of the three dashes. These data were calculated from the same experiments 
represented in panels C and D. F) Bar graph illustrating average Z-prime scores from 
three independent replicate experiments, each consisting of 30 biological positive 
control replicates and 30 biological negative control replicate measurements. Each 
bar represents a different pair of positive and negative control reagents measured 
using dsRNA/CellTiter-glo or VDA assays as indicated. Error bars indicate standard 
error of the mean. G) Results from VDA assays targeting 30 different genes as 
indicated. Each bar represents a different shRNA reagent (3 per gene). Blue bars 
indicate samples with VDA-score greater than 0.1 and black bars represent VDA-
scores less than 0.1. H) Graph displaying VDA results as in panel G but with VDA 
analysis performed including cell size correction. 
 
Figure 3: An integrated network analysis of TSC dependencies. A) Venn 
diagram showing overlap of genes between the top 20 ranked hits from the VDA or 
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dsRNA screens performed in TSC1 or TSC2 cells. B) Network diagram showing 
genes identified as SS/L with TSC1 and/or TSC2. Circles represent individual genes 
identified from dsRNA screens (blue) or VDA screens (red). Symbol shapes indicate 
confidence with which hits from dsRNA screens were identified (diamond – high 
confidence, square – medium confidence and triangle – low confidence). Gene 
cluster functions were defined based on manual curation of component functions.  
 
Figure 4: Identification of drugs with selective effects on TSC deficient cells. A-
D) Bar graphs illustrating cell viability as measured using CellTiter-glo assays in the 
presence of the indicated drugs, normalized to vector alone. Bars represent the 
average of at least six replicate measurements in either wild-type (blue bars) or 
TSC1/2-deficient (orange bars) (B and C) or TSC1/2-deficient cells with empty vector 
(orange bars) or TSC1/2 cDNA (blue bars) addback (D and E) cells as indicated. 
Error bars indicate standard error of the mean. Human-RA indicates human RA-
derived cells and human-BC indicates human bladder cancer-derived cells. 
 
Figure S1: Drug selectivity does not correlate with selectivity of target genes in 
genetic assays. The two graphs illustrate results from viability assays performed 
with 9 different FDA-approved drugs in wild-type and TSC1/2 deficient cells. Each 
circle represents a drug classified as selective (a greater viability effect on TSC1/2 
deficient cells compared to wild-type) or non-selective. Drug selectivity is compared 
to selectivity scores in dsRNA screens (Z score in wild-type cells minus Z-score in 
TSC1/2 deficient cells) or VDA screens (see methods for calculation of VDA score). 
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